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HORIZONS OF ATHEROSCLEROSIS 
RESEARCH AND THERAPY 
Peter Libby 
Brigham and Women's Hospital and Harvard Medical School 
Boston, Mass 
The treatment of coronary artery disease has wit- 
nessed a revolution i  the last quarter century. We have 
mastered the diagnosis of coronary stenoses and car- 
diac ischemia. We have t hand an array of extremely 
effective therapies for treating ischemia, including 
medical therapy, and percutaneous and surgical revas- 
cularization. Yet, these modalities do not prolong life 
or prevent myocardial infarction except in selected 
subgroups. With regard to coronary risk reduction, we 
have also made considerable progress. Data from mul- 
tiple clinical trials with LDL lowering agents have fially 
vindicated the "cholesterol hypothesis," documenting 
a reduction in coronary events and reducing all-cause 
mortality. Yet, even the most effective current hera- 
pies fail to prevent the majority of coronary events, and 
most patients with atherosclerosis have LDL levels in 
the "average" range. Thus, much remains to be done 
to combat he residual burden of atherosclerotic dis- 
ease. In preparation for this task, we need to take into 
account shifting demographics and the merging ther: 
apeutic targets. We will witness manifold emograph- 
ic changes in coronary disease the next 20 years. The 
most important will be Globalization, Aging, and 
increasing adiposity and hence, the insulin resistance 
syndrome. New therapeutic opporttmities will include 
aspects ofdysllpidemias beyond LDL, including strate~ 
gies to manipulate HDL (eg, Apo A-l, CETP, SRB-1, 
ABC-1), and "diabetic dyslipidemia" (PPAR-alpha 
agonists and insulin sensitizers including the PPAR- 
gamma gonists). Novel lipid-directed therapeutic tar- 
gets also include cholesterol absorption and ACAT 
inhibitors. Aside from strategies targeting lipids, we 
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will need to seek more information about nontradi- 
tional risk factors and their treatment, including 
antioxidants, Lp(a), homocysteine, and infectious 
agents. Although we can look back with some satisfac- 
tion on the advances of recent years in treatment of 
atherosclerosis, wemust not become complacent, but 
pursue new avenues to limit even further the world- 
wide spread of this major cause of illness and death. 
VEGF- INDUCTION OF ANGIOGENESIS 
Jeffrey M. Isner, MD 
St Elizabeths Medical Center 
Boston, Mass 
The therapeutic implications of angiogenic growth 
factors were identified by the pioneering work of 
Folkman and colleagues over two decades ago. 1 Their 
work documented the extent o which tumor devel- 
opment was dependent upon neovascularization a d 
suggested that this relationship might involve angio- 
genic growth factors that were specific for neoplasms. 
Subsequent i vestigations have established the f asibil- 
ity of using recombinant formulations of such angio- 
genic growth factors to expedite and/or augment col- 
lateral artery development in animal models of 
• myocardial nd hindlimb ischemia. This novel strategy 
for the treatment ofvascular insufficiency was termed 
therapeutic angiogenesis. 2 More recent data suggest 
that the basis for native as well as therapeutic neovas- 
cularization is not restricted to angiogenesis, but 
includes postnatal vasculogenesis a well. Data sup- 
porting these notions as well as derivative concepts and 
concerns are the subject of this Perspective. 
Therapeutic angiogenesis 
Preclinical studies established that angiogenic 
growth factors could promote collateral artery 
development in animal models of peripheral and 
myocardial ischemia (reviewed in 3). Morphometric 
analyses documented that such enhanced vascularity 
encompassed a range of vessel caliber, from medi- 
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urn-sized arteries visualized by premortem angiogra- 
phy to increased capillary density demonstrated in 
postmortem histology. The median range of new 
vessel growth, however, appears kewed to smaller 
caliber arteries less than 180 g in diameter. Indeed, 
there is good reason to suspect that a proportion of 
newly recognized medium-sized arteries may devel- 
op as a result of "arteriogenesis" (ie, in situ prolifer- 
ation of preexisting arteriolar connections into larg- 
er collateral vessels). 4 Whether such remodeling 
occurs as a direct result of growth factor modulation 
or as a flow-mediated response to augmented down- 
stream capacitance r mains to be determined. 
The angiogenic growth factors employed in these 
preclinical studies have been administered as recom- 
binant protein or by gene transfer, and include vas- 
cular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF)-I, FGF-2, and hepatocyte 
growth factor (HGF). More recently, a drug--the 
angiotensin-converting enzyme (ACE) inhibitor, 
quinapralatS--and naked DNA encoding for the 
transcription factor hypoxia inducible factor-1 (HIF- 
1) 6 have each been shown to enhance neovascular- 
ization in the rabbit ischemic hindlimb model. 
The optimal preparation and delivery strategy for 
therapeutic neovascularization is the subject of 
ongoing clinical investigation. The potential 
requirement to maintain a suitably high and local 
concentration over a period of days to weeks consti- 
tutes an advantage for gene transfer versus recombi- 
nant protein therapy. While viral vectors 7 may 
enhance transfection efficiency and thus yield higher 
levels of gene expression, this may be less relevant to 
strategies in which gene products such as VEGF 
include a signal sequence, which permits active 
secretion from intact cells; previous studies from our 
laboratory 8 have documented that naked DNA that 
encodes for a secreted protein--as opposed to pro- 
teins that remain intracellular--can yield meaningful 
biological outcomes because of paracrine ffects of 
the secreted gene product. 
Proof of concept for the notion that therapeutic 
angiogenesis could be successfully extended to human 
subjects was first demonstrated using gene transfer of 
naked DNA encoding for VEGF (phVEGF) for the 
treatment of critical limb ischemia. 9 Treatment was 
initiated with 100 mg ofphVEGF using a dose-esca- 
lating design. Three patients presenting with rest pain 
(but no gangrene) and treated with 1000 mg were 
subsequently shown at 1-year follow-up to have 
improved blood flow to the ischemic limb and remain 
free of rest pain. With the increase in dose of 
phVEGF165 to 2000 gg angiographic and histologic 
evidence of new blood vessel formation became 
apparent. 9 More recently, the use of intramuscular 
gene transfer, employed initially as a means of treating 
patients in whom vascular disease in the ischemic limb 
was too extensive to permit an intra-arterial approach, 
achieved marked improvement in collateral vessel 
development in patients with critical imb ischemia. ]° 
Objective findings of bioactivity in this preliminary 
report included improvement in the ankle-brachial 
index, angiographic evidence of newly visible collater- 
al blood vessels, and demonstration by magnetic res- 
onance angiography of improved lower extremity 
blood flow. Ischemic ulcers healed or markedly 
improved in four of seven limbs, including successful 
limb salvage in three patients recommended for 
below-knee amputation. 
Successful application of both gene transfer and 
recombinant protein administration for the treat- 
ment of myocardial ischemia in human subjects was 
reported in 1998. The former involved direct 
intramyocardial njection ofphVEGF as sole therapy 
for myocardial ischemia refractory to conventional 
therapy. 11 Among 24 consecutive patients treated 
with this strategy to date, anginal episodes requiting 
sublingual nitroglycerin were reduced from nearly 
60 per week to less than three per week. Objective 
evidence of improved per fusion was documented by 
a near doubling of treadmill exercise time, and 
improved myocardial blood flow on stress as well as 
resting nuclear perfusion scans. The improvement in 
perfusion observed at rest is consistent with resolu- 
tion of hibernating myocardium, a finding that has 
been recently confirmed using catheter-based 
electromechanical mapping. 12 Recombinant protein 
administration using FGF-1 has also been reported 
to augment myocardial revascularization and 
improve functional status in patients undergoing 
concurrent coronary artery bypass urgery. 13 
In vitro studies have suggested certain mecha- 
nisms that may have contributed to the apparent 
benefit as well as safety of phVEGF gene transfer in 
these early trials. While ECs were previously viewed 
solely as the target for VEGF, it is now clear that 
ECs subjected to hypoxia can synthesize VEGF as 
well. 14 This autocrine feature of VEGF creates the 
opportunity for amplifying the effects of even a small 
amount of exogenous VEGF, as EC proliferation in 
the ischemic territory creates additional potential 
cellular sources of VEGF synthesis and secretion. 
Moreover, the recent observation that VEGF may 
upregulate its own (VEGFR-2 or KDR) receptor 15 
establishes a second basis for autocrine and paracrine 
amplification. 
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VEGF has also been shown to inhibit EC apop- 
tosis by activating the serine-threonine protein kinase 
Akt through a process requiring integrin ligation. 16 
This finding suggests a mechanism other than mito- 
genesis by which a net increase in EC viability may be 
accomplished. Given the limited twofold to fourfold 
increase shown for VEGF on cellular proliferation, it
is possible that the contribution of enhanced EC sur- 
vival under conditions of severe ischemia is critical to 
the proangiogenic effects of VEGF and other angio- 
genic growth factors. 
The preclinical and clinical studies of therapeutic 
angiogenesis performed to date have repeatedly 
shown that VEGF-induced angiogenesis is not indis- 
criminate or widespread, but is instead restricted to 
sites of ischemia. This appears to result from 
paracrine upregulation of the principal high-affinity 
VEGFR-2 (KDR) receptor in response to factors 
released from hypoxic skeletal myocytes. 17 Receptor 
upregniation on ECs within the region of lower limb 
or myocardial ischemia thus enables these cells to act 
as magnets for any VEGF secreted into the ischemic 
milieu. Only when VEGF expression is locally pro- 
tracted at high levels has it been possible to violate 
this principle. 18 
Risk factors for neovascularization 
Preliminary clinical findings in patients with criti- 
cal limb ischemia indicated that the response to 
phVEGF gene transfer was most robust and expedi- 
tious in young patients with premature atherosclero- 
sis involving the lower extremities, so-called Buerger's 
disease. 19 This clinical observation was supported by 
experiments performed in live animal models, specifi- 
cally young (4-5 years) versus old (6-8 months) rab- 
bits and young (8 weeks) versus old (2 years) mice. In 
both cases, native neovascularization f the ischemic 
hindlimb was markedly retarded in old versus young 
animals. Retardation of neovascularization n old ani- 
mals appeared in part to result from reduced expres- 
sion of VEGF in tissue sections harvested from the 
ischemic limb. 2° Similarly retarded neovascularization 
and reduced VEGF expression were observed in dia- 
betic (NOD) 21 and hypercholesterolemic (ApoE-/-) 
mice. 22 Cell-specific immunostaining localized VEGF 
protein expression to skeletal myocytes and infiltrat- 
ing T cells in the ischemic fimbs of C57 mice; in con- 
trast, VEGF-expressing T cell infiltrates were found to 
bc severely reduced in ischemic limbs of mice in 
which angiogenesis was impaired. Transendothelial 
migration of human T cells has been previously 
shown to be compromised in elderly versus young 
subjects, although the basis for this defect in transmi- 
gration remains enigmatic. 23 The critical contribution 
of T cells to VEGF expression and collateral vessel 
growth has been reinforced by the finding of acceler- 
ated limb necrosis in athymic nude mice with opera- 
tively induced hindlimb ischemia. 22 
Reduction in endogenous VEGF expression, 
however, was not the only factor contributing to 
impaired neovascularization in these animals; older, 
diabetic, and hypercholesterolemic animals--like 
patients--also exhibit age-related endothelial dys- 
function, manifest as reduced vasodilation and 
decreased production of NO in response to endothe- 
lium-dependent agonists. 2° Endothelial dysfunction 
did not preclude a favorable response to cytokine 
replacement therapy; indeed, the absolute magnitude 
by which blood pressure ratio, angiographic score, 
and capillary density were increased in response to 
supplemental dministration of recombinant VEGF 
protein was similar for young and old animals. In 
older animals, however, these indices failed to reach 
the ultimate levels recorded in younger animals, 
apparently reflecting the inherent limitations 
imposed by a less responsive EC substrate. 
This clinical experience and these animal studies 
have two implications. First, the findings suggest 
that the fundamental mechanism by which thera- 
peutic neovascularization augments collateral devel- 
opment is to provide cytokine supplements o indi- 
viduals who, because of advanced age, diabetes, 
hypereholesterolemia, and/or other as yet unde- 
fined circumstances, are unable to appropriately 
upregnlate cytokine xpression i  response to tissue 
ischemia. In this regard, ligand supplementation 
may be analogous to erythropoietin administration 
in patients with refractory anemia. 
Second, cytokine administration clearly comprises 
only one aspect of the therapeutic intervention. 
Regardless of how much ligand is administered, the 
resident population of ECs that is competent to 
respond to an available level ofangiogenic growth fac- 
tors may also constitute a potentially limiting factor in 
strategies designed to promote neovascularization f 
ischemic tissues. A reasonable goal may therefore con- 
sist of developing a complementary strategy that 
would provide substrate together with ligand, a "sup- 
ply side" version of therapeutic neovascularization. 24 
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DELIVERY OF FGF-FAMILY PEPTIDES FOR 
NEOVASCULARIZATION 
Christian Haudenschild, MD
George Washington University Medical Center 
The idea that we might  be able to control  selec- 
tively the format ion o f  b lood vessels keeps attracting 
investigators and investors as well: suppress anglo- 
genesis and thus inhibit  the growth o f  tumors,  or  
provoke it and thus revascularize ischemic tissues, 
and two major killers, cancer and atherosclerosis, are 
el iminated! Whi le this is clearly a naive oversimplifi- 
cat ion,  it is still very  impressive to observe new 
b lood vessels reach toward a corneal pocket  contain- 
ing a piece o f  tumor  or a pellet slowly releasing FGF  
in the best  establ ished in vivo angiogenes is  test. 
Many o f  the other tests cover at least some partial 
aspects o f  angiogenesis  uch as endothe l ia l  cell 
migrat ion, prol i feration, enzymatic activity, or  tube 
formation,  and representative members  o f  the FGF  
family are positive in all o f  these assays. Having FGF  
as a defined pept ide rather than an obscure extract 
and knowing much about  its angiogenic and other 
propert ies,  why has there not  been more sustainable 
progress applying this (and many other  "growth"  
factors) for therapeutic neovascularization in vivo? 
While it is impossible to predict  all interactions o f  
a new therapeutic agent in vivo, some fundamental  
rules observed in tissue culture should not  be over- 
looked. For  example, FGF- I  needs to be applied to 
